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Abstract
Background: Access to qualitative HIV PCRs for early infant diagnosis (EID) is restricted in resource-limited settings
due to cost. We hypothesised that pooling of dried blood spots (DBS), defined as combining multiple patient
samples in a single test with subsequent individual testing of positive pools, would be cost saving while retaining
clinical accuracy compared to individual patient testing.
Methods: Cost savings: A model was developed to simulate reagent and consumable cost saving of pooled compared
to individual sample testing. Daily sample/result data of a public health laboratory in South Africa were used to illustrate
outputs from the model. Samples were randomly allocated to pools and the process was repeated 1000 times to measure
variation in estimates due to this stochasticity.
Clinical accuracy: 1170 patient samples were tested using the Roche CAP/CTM Qual assay in pools of five 50 μl DBS.
Negative pools comprised DBS previously tested in single reactions; positive pools included 1 positive sample.
Results: Pooling would have saved 64% of laboratory costs in 2015. The model is published as an R-based web tool, into
which the user enters sample/positivity estimates and workflow management parameters to obtain cost saving estimates
at an optimal pool size.
Sensitivity of pooled testing was 98.8% overall; 100% for strongly reactive pools. One pool tested false positive which
would not impact clinical specificity as individual patient testing is performed prior to reporting.
Conclusions: Pooled PCR testing for EID remains accurate and dramatically reduces costs in settings with moderate to
low prevalence rates and sufficient sample numbers.
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Background
Early infant diagnosis (EID) of HIV infection in
HIV-exposed infants currently requires polymerase
chain reaction (PCR) to identify and treat HIV-infected
infants promptly and thereby improve their prognosis
[1]. However, PCR testing for EID can be prohibitively
expensive in resource limited settings where the burden
of disease is significant, limiting access to care [2]. Strat-
egies to increase EID testing coverage are thus required.
The World Health Organization (WHO) recommends
PCR testing for all HIV-exposed infants at 4–6 weeks of
age using EDTA whole blood, plasma or dried blood
spots (DBS) [3], while the importance of testing infants
at birth has recently been emphasised [4]. Reducing the
cost of EID testing would enable programmes to include
PCR testing at additional timepoints, e.g. at birth or later
during infancy, without increasing the total cost. Timely
diagnosis and treatment initiation would in turn further
curb HIV-related morbidity and mortality in this vulner-
able population.
A pooled EID testing algorithm involves the PCR
screening of a specimen pool comprising multiple indi-
vidual patient specimens, followed by individual testing
(referred to as pool deconvolution) only if a pool screens
positive. As all individual samples in a negative pool are
regarded as negative it results in substantial cost savings
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when a large proportion of pools tests negative. This ap-
proach is efficient in blood donor screening [5] and in
HIV treatment failure detection by quantitative HIV-1
RNA testing of both plasma [6] and DBS specimens [6,
7].
In this study we demonstrate, through modelling, the
cost efficiency of pooled EID testing at varying HIV
positivity and sample throughput rates, as well as the
clinical accuracy of pooled EID testing compared to in-
dividual patient whole blood EID testing in a public
health laboratory in Cape Town, South Africa.
Methods
Study design and ethical approval
This was a retrospective, laboratory-based study per-
formed at the Division of Medical Virology, Department
of Pathology, National Health Laboratory Service
(NHLS) Tygerberg and Stellenbosch University. Ethical
approval was obtained from the Health Research Ethics
Committee of Stellenbosch University with reference
number N14/02/013.
Contextual analysis
In order to assess specimen flow and positivity rate in the
abovementioned laboratory, we queried routine PCR data
from the Disa*Lab laboratory information system (Labora-
tory System Technologies (Pty) Ltd., Bedfordview, South
Africa). Routine HIV PCR data was obtained by extracting
the following parameters from the local Medical Virology
NHLS database: unique laboratory reference number, pa-
tient name and surname, patient date of birth, sample
processing date, sample result. Patient records were linked
using LinkPlus software (CDC, Atlanta) to determine the
final HIV status of presumed low positive samples, where
after all records were de-identified.
Reference samples used for pooling evaluation
Per laboratory standard operating procedure, the labora-
tory routinely stores residual EID samples as 50 μl DBS
after routine diagnostic testing using 100 μl EDTA whole
blood on the Roche Cobas AmpliPrep/Cobas Taqman
HIV-1 Qual (CAP/CTM, Roche Molecular Systems, Inc.,
Branchburg, NJ) assay has been completed. The Roche
CAP/CTM is a total nucleic acid real-time PCR assay
that detects HIV-1 proviral DNA and HIV-1 RNA [8].
The assay is suited for EID testing in high burden areas
as it is a high-throughput, automated system, which can
test both whole EDTA blood and DBS samples.
Stored DBS are identified by unique laboratory refer-
ence numbers. Previously confirmed negative DBS,
tested in single reactions with the reference PCR
method, were combined to constitute negative pools.
Positive pools were constituted by combining one DBS
from a patient with a positive reference result with
negative dried blood spots. A subset of the positive pools
were based on ‘low positive’ samples, i.e. samples initially
categorised as indeterminate (CAP/CTM cycle threshold
values ≥32 and/or relative fluorescence values ≤5) but
who were proven to be HIV infected at later time points.
This was necessary as patients with such low positive
results were previously shown to have a reduced prob-
ability of testing positive at a later time point [9, 10].
Pre-analytical DBS manipulation
Due to effective prevention of HIV mother to child
transmission (PMTCT) programmes, the prevalence of
HIV infection in young infants in South Africa is now
low [2]. With a very low prevalence the optimal theoret-
ical pool size is large as most pools would remain nega-
tive, realising maximal cost savings for larger pools.
Apart from the theoretical optimum we included other
considerations: 1) the maximum number of DBS which
could fit into a single reaction tube, 2) whether DBS
could be added to a Roche S-tube directly or whether
elution of DBS should be done as additional step with-
out resulting in reaction inhibition (Roche specimen
pre-extraction reagent [SPEX] was used as DBS eluant
throughout), and 3) the sensitivity of pooled HIV PCR
testing.
Pooled testing model
A model was developed to simulate yearly cost savings
of a pooled testing approach compared to individual
DBS testing. Daily sample and result data of the NHLS
Medical Virology laboratory for the period 1 January
2009 to 31 July 2015 were used for the simulation (Add-
itional file 1). The model assumed a minimum batch size
of 10 samples for individual testing and 20 samples
when pooling (i.e. between 4 and 10 pools at different
pool sizes), to maintain a good turn-around time while
maintaining batches of adequate size to justify the use of
the instrument and laboratory personnel time.
Remaining samples after minimum batch sizes were
filled were added to the following day’s runs. For the ob-
servation period, the model simulated the number of
positive pools when randomly allocating samples tested
on a particular day to varying pool sizes from 2 to 5 with
deconvolution of positive pools by individual testing,
done the following day. This random allocation was re-
peated 1000 times, for each pool size, to estimate the
mean values and variability in model output. Bootstrap
confidence intervals around mean estimates are given by
the 2.5th and 97.5th percentiles of the 1000 estimates.
Only the cost of reagents and consumables is consid-
ered. Labour costs and laboratory overheads, such as
electricity and equipment costs, are not considered.
The model to estimate cost-efficiency of the pooling
approach was implemented in the statistical software R
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[11] and a web-based tool was created using the Shiny
package, accessible at: https://carivs.shinyapps.io/Calcu-
lator/. The user can enter average daily sample through-
put, workflow management parameters, expected infant
HIV positivity rate and reagent costs in US dollar. The
model produces estimates of costs and batched runs
saved at the optimal pool size, and a plot of cost savings
as a function of pool size and positivity.
Results
Practical evaluation of different DBS pooling approaches
Adding more than two whole DBS directly into an
S-tube is not practical as DBS would not adhere to the
side of the tube, thereby mechanically obstructing the
CAP/CTM aspiration probe. After experimenting with
DBS cut into quarters, halves or kept whole, it was
found that a maximum of 5 dB, each cut into halves,
could fit into a 2 ml Eppendorf tube together with
1450 μl SPEX before continuously mixing the tube at 56
C for 30 min (the current standard practice for individ-
ual DBS testing). The resulting eluate of approximately
1100 μl was then transferred to an S-tube by manual
pipetting.
The time taken to process DBS specimens for individ-
ual testing was measured and compared to time taken to
prepare a similar number of DBS specimens for pooled
testing, and was found to be similar.
Clinical accuracy of pooling
A total of 1170 unique patient specimens were used to
construct 149 positive, 18 low positive and 67 negative
pools (Table 1). All positive pools tested positive and all
but one of the negative pools tested negative. This re-
sulted in a pool level specificity of 98.5%; the expected
specificity at patient level would be higher as each sam-
ple contributing to a positive pool must be re-tested in-
dividually prior to reporting.
Two of the low-positive pools did not test positive,
resulting in an overall sensitivity of 98.8% in the test
population. However, for one of the two patients a sec-
ond DBS of the indeterminate sample was available to
be re-tested individually, with a negative result. This sug-
gests a very low HIV viral load, which was only detected
when using the larger (100 μl) whole blood input
volume, so in this case pooling would not have had any
clinical impact compared to individual DBS testing.
Application of the cost-efficiency model simulation to
laboratory data
From January 2009 to July 2015, the Medical Virology
laboratory received an average of 45 samples per day
with an overall positivity rate of 5.7% (Table 2). The ob-
served increase in overall sample positivity observed
from 2013 to 2014 coincides with a change in infant
testing policy rather than a failure of PMTCT strategies.
Since 2014, all positive infant PCRs are recommended to
be confirmed by a second qualititative HIV-1 PCR rather
than the previously recommended HIV RNA load test.
Figure 1a shows the percentage cost that would have
been saved each year if this lab used pooling instead of
individual testing. In 2015, the expected savings would
have been 43.3% (95% CI, 43.3–43.5%) of reagent and
consumable costs if two samples were pooled and up to
63.5% (95% CI, 63.1–64%) if five samples were pooled.
Figure 1b shows the percentage of batched runs saved
when using a pooling approach compared to individual
testing. From 2013 to 2015 this laboratory could have
saved half of the batched runs had it used pool sizes of
three to five instead of individual testing.
Discussion
With this study, we modelled the cost efficiency of
pooled EID testing at varying HIV PCR positivity rates
and estimated the real-life clinical accuracy of pooled
EID testing compared to individual patient whole blood
EID testing in a public health laboratory in Cape Town,
South Africa.
In order to assess the impact of pooling over a longer
period we performed a simulation using real daily indi-
vidual test results. We established that pooling could re-
duce reagent and consumable related costs by 63.5% in
our setting, which has a low expected rate of positive la-
boratory results. In addition we created a useful tool for
laboratory managers to estimate savings and predict the
optimal pool size for EID testing based on the user’s
local HIV PCR result data. It is important to note that
expected laboratory PCR positivity rates should be used
in the estimation and not the expected population preva-
lence of infant HIV infection, as an individual patient
may have two consecutive positive PCR tests as a con-
firmation of HIV status which will influence the
efficiency of pooling. While personnel time spent to pre-
pare pooled runs compared to individual DBS runs was
similar, the median number of runs per day can be
reduced through pooling. In settings where diagnostic
service bottlenecks result from limited instrument avail-
ability, pooling may therefore relieve such bottlenecks
and result in an improved turnaround time from sample
Table 1 Clinical performance of pooled testing compared to
Roche CAP/CTM reference results




Positive pools 149 (100) 0 149
Low positive pools 16 (89) 2 (11) 18
Negative pools 1 (1.5) 66 (98.5) 67
Total 166 68 234
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acquisition to result reporting. A reduction in the num-
ber of runs required may in addition allow instruments
to be used for other critical tests, such as HIV viral load
testing. With the online tool, users further have the abil-
ity to set the minimum number of samples that will be
required to perform pooled testing to individualise this
process for their setting. Using the most recent UNAIDS
estimates of the final mother-to-child transmission rates
in 21 sub-Saharan African countries [2], a laboratory in
a setting like South Africa with an estimated transmis-
sion rate of 4% and a moderate throughput of 70 speci-
mens per day would save 62% of reagent and
consumable costs using pools of 5 specimens while re-
ducing the number of instrument batched runs from 3
Table 2 Daily average specimen numbers for EID testing as well as cost savings at varying pool sizes, per annum, Division of
Medical Virology, National Health Laboratory Service Tygerberg and Stellenbosch University




% Cost saved (95% CI) % Batched runs saved (95% CI)
Pool size = 2 Pool size = 5 Pool size = 2 Pool size = 5
2009 39 (26) 10.0 32 (31.7–32.3) 41 (40.1–42) 32 (31.2–32.8) 29.3 (27.7–31)
2010 35 (17) 9.0 34 (33.7–34.3) 44.3 (43.3–45.2) 31.1 (30.3–31.9) 28.8 (27–30.6)
2011 36 (18) 6.8 39.6 (39.4–39.8) 52.8 (52–53.5) 31.1 (30.4–32) 32.2 (30.7–33.8)
2012 40 (17) 5.1 43.1 (43–43.3) 59.7 (59.2–60.3) 37.2 (36.6–37.9) 40.4 (39.2–41.5)
2013 48 (21) 3.6 44.2 (44.1–44.4) 64.3 (63.9–64.7) 40 (39.5–40.4) 51.2 (50.4–52.1)
2014 55 (19) 4.3 42.6 (42.5–42.7) 61 (60.6–61.5) 39.8 (39.3–40.3) 50.9 (49.8–51.9)
2015 67 (26) 3.6 43.3 (43.3–43.5) 63.5 (63.1–64) 40.8 (40.4–41.3) 54.5 (53.3–55.7)
Overall 45 (23) 5.7
SD Standard deviation, CI Confidence interval
Fig. 1 a Estimated % reagent and consumable cost saving at varying pool sizes and positivity rates, b Estimated % of batched testing runs saved
at varying pool sizes and positivity rates
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to 2. Similarly, in a laboratory in a high volume, high
burden setting that performs 130 tests per day at a
MTCT rate of 9%, testing pools of 4 specimens would
save 44% of costs and reduce the number of batched
runs from 6 to 4. This may have a significant impact on
the turnaround time of patient result reporting as it
would allow all specimens to be tested in an 8 h work
day if the Roche CAP/CTM platform is used without
the need for additional instrumentation or extended
working hours.
EID pooling using 50 μl DBS was importantly found to
have an acceptable clinical sensitivity and specificity
compared to testing 100 μl whole EDTA blood. Of the
18 pools consisting of one low positive DBS and four
negative DBS, pooling failed to pick up two. Although it
is important to detect samples with low HIV RNA levels,
we could not include more such samples due to the rela-
tive shortage thereof. These samples comprised approxi-
mately 11% of the positive DBS pools in the study
population, whereas only approximately 0.5% of all in-
fant PCRs conducted in the investigating laboratory were
reported in this category. The impact of a reduced sensi-
tivity for this result category when using pooled testing
is therefore limited, and the actual sensitivity when pool-
ing all routine PCR samples is expected to be greater
than the observed 98.8% sensitivity. It is further import-
ant to note that pooled DBS testing was compared to
higher volume individual whole EDTA blood reference
results, and a direct comparison between pooled DBS
testing and individual DBS testing may have had even
more favourable results. In the single case where a sec-
ond stored DBS was available, individual DBS testing
also reported a negative result.
Regarding the specificity of pooled testing, one of 68
expected negative pools were reported as positive. We
previously reported a reduced specificity of the CAP/
CTM assay [9], and the required deconvolution of all
positive pools implies that all patients from a positive
pool would receive individual DBS testing. Pooling
therefore does not compromise the test’s specificity
compared to individual DBS testing.
The main limitation of pooled EID testing is an in-
creased turnaround time for positive samples (as these
would require deconvolution and subsequent individual
testing) as well as samples that are too few to complete
a pool on the day of receipt which will be included in
the next day’s testing. We therefore advise that the on-
line tool be used to determine whether a site’s antici-
pated sample numbers and positivity rate would realise
significant savings.
Conclusion
EID pooling proved to be a cost-efficient alternative to
individual patient testing. Costs saved by introducing
pooled testing could be utilised to improve the coverage
and/or frequency of EID testing, or could be used to im-
prove other components of an HIV programme.
Additional file
Additional file 1: NHLS Tygerberg data. This file contains the daily
number of infant blood samples received at this lab and the number
testing HIV positive between January 2009 and July 2015. (CSV 50 kb)
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